Overview: S100B Marker Rapid TestIntroduction: The S100B Marker Rapid Test is a diagnostic tool designed to detect S100B levels in serum or plasma samples, facilitating the screening of brain injury or melanoma. Associated with traumatic brain injury or metastatic melanoma, this neurologic or oncologic condition presents with confusion, skin changes, and severe complications like coma or metastasis if untreated, particularly in individuals with head trauma or skin lesions. Per the 2023 American Academy of Neurology guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in clinical pathology settings. This rapid diagnostic falls under clinical pathology and targets individuals with neurologic or dermatologic symptoms, addressing the challenge of early detection to guide supportive care or surgery. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing complications. Its multi-sample capability enhances its utility.Other Names: S100B Rapid Test.FDA Status: FDA approved, CLIA certified for clinical pathology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Roche, this test advanced biomarker detection, providing a rapid alternative to traditional assays.Purpose: The test screens for S100B to guide brain injury or melanoma diagnosis, assess tumor or neurologic status, and inform treatment and prevention strategies.Test Parameters: Presence of S100B, detected with reasonable specificity to indicate brain damage or cancer activity, typically detectable in serum or plasma at elevated levels during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report confusion, skin changes, or recent head trauma.Specimen: Serum 2-5 mL, Plasma 2-4 mL, collected using sterile SST or EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve marker integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade markers, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on confusion, skin changes, prior brain injury, or family history of oncologic disease, as well as any recent trauma or treatments.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated conditions including coma or metastasis, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent therapy can affect results. Correlation with imaging or biopsy is recommended to confirm findings.Clinical Significance: A positive result indicates possible brain injury or melanoma, necessitating further investigation like imaging or oncology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during early stages.Specialist Consultation: Neurologists or oncologists should be consulted for case management, treatment planning, and coordination with disease programs.Additional Supporting Tests: CT scan, biopsy, or LDH for confirmation.Test Limitations: The test may produce false positives in inflammation or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.References: AAN Guidelines 2023, Journal of Neurology 2024, Pathology 2025.